clonal hematopoiesis of indeterminate potential
Conditions
Interventions
Group 1: female breast cancer patients >= 60 years of age firstly diagnosed with breast cancer at a curative stage. Prior to the start of breast cancer therapy, a diagnostic test for CHIP from periphe
afterwards, patients will receive a questionaire on patient satisfaction and possible fears with regard to CHIP.
Sponsors
Universitätsklinik Essen
Eligibility
Sex/Gender
Female
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: First diagnosis of non-metastasized breast cancer
Exclusion criteria
Exclusion criteria: Male gender Metastasized breast cancer Former history of acute myeloid leukemia, myeloproliferative diseases, or myelodysplastic syndrome Prior therapies with cytotoxic agents (excluding methotrexate for autoimmune diseases)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the willingness of participation with an accuracy of +/- 7.5%. | — |
Secondary
| Measure | Time frame |
|---|---|
| - to assess the patient acceptance of the study procedures and addition of CHIP diagnostics to the routine work-up - to evaluate the overall prevalence of pre-therapeutic CHIP in this cohort of breast cancer patients - to characterize the prevalence of cardiovascular risk factors in CHIP-positive versus CHIP-negative patients | — |
Countries
Germany
Contacts
Public ContactNina Rosa Neuendorff
Universitätsklinik Essen
Outcome results
None listed